This study evaluated the 7-year follow-up remission rate and maintenance in patients with rheumatoid arthritis (RA) under real-life conditions and identified factors related to long-term remission. The authors concluded that at 7 years nearly twice as many patients were in remission than at 1 year of follow-up and those patients had mainly received co-prescription with disease-modifying anti-rheumatic drugs (DMARDs).

This study evaluated the safety profile of palbociclib (Ibrance) combined with either fulvestrant (Faslodex) or letrozole (Femara) in patients with hormone-receptor-positive (HR+) and HER2 negative (HER2 -) advanced breast cancer (BC). The data showed that both palbociclib regimens were safe and tolerated in these patients with some rare side effects of venous thromboembolism (VTE) and interstitial lung disease (ILD).

This review evaluated the safety and effectiveness of vitamin E supplementation in patients with rheumatoid arthritis (RA). The authors concluded that regular supplementation with vitamin E can help to improve the overall quality of life (QoL) in patients by reducing joint discomfort, swelling due to excessive fluid buildup in tissues (edema), and joint stiffness.

This analysis compared the effectiveness of different acupuncture therapies combined with disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis (RA). The data indicated that RA disease activity was most improved by combining electro-acupuncture and DMARDs while fire-needle or moxibustion plus DMARDs were most effective at improving pain and reducing inflammation.

This study evaluated the impact of immune checkpoint inhibitors (ICIs) on COVID-19 outcomes in patients with cancer. The data showed that the use of ICI treatment before COVID-19 infection does not affect the disease severity or survival outcomes. This study supports the continued use of ICIs in cancer patients during the pandemic.

This study evaluated the effectiveness and safety outcomes of extending treatment with letrozole (Femara), an aromatase inhibitor, to 10 years in postmenopausal patients with hormone receptor-positive (HR+) early-stage breast cancer (BC). The data showed that extending treatment with letrozole to 10 years significantly improved the disease-free survival rates in these patients.

This study identified predictors of disease flare in patients with early, active rheumatoid arthritis (RA) that had stopped methotrexate (MTX; Otrexup) and/or abatacept (Orencia) treatment after clinical remission was achieved at 12 months. The data showed that patient function (HAQ-DI) and bone erosion based on magnetic resonance imaging (MRI) scans predicted disease flare at 6 months and 12 months after treatment withdrawal.

This study evaluated the effectiveness of antiresorptive drugs on bone mineral density (BMD) in postmenopausal women with early-stage breast cancer (BC) receiving treatment with aromatase inhibitors (AIs). The data showed that denosumab (Prolia) and zoledronic acid (Aclasta) were the most effective antiresorptive treatment options to improve BMD in these patients.

This review evaluated the effectiveness of denosumab (Prolia) on bone mineral density (BMD) and joint destruction in patients with rheumatoid arthritis (RA). The authors concluded that denosumab treatment was linked to increased BMD and reduced joint destruction in patients with RA.

This study investigated the effect of filgotinib (Jyseleca) on patient-reported outcomes (PROs) and health-related quality of life (HRQoL) in patients that had active rheumatoid arthritis (RA). The study showed that filgotinib improved PROs in these patients and can be a treatment option for patients with insufficient responses to methotrexate (Otrexup; MTX), biological disease-modifying anti-rheumatic drugs (bDMARDs), and those that are MTX-naive (have never received MTX).